Corvus Pharmaceuticals to Engage with Investors at Major Conference
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, is making waves in the healthcare arena. The company recently announced that its leadership team will host one-on-one meetings with investors and participate in a fireside chat at a notable annual healthcare innovation conference. This event unfolds in Boston, where Corvus aims to foster deeper relationships with potential investors and stakeholders.
Fireside Chat and Investor Meetings
The fireside chat is scheduled for Monday, November 10, 2025, at 8:30 am ET. This presentation is an opportunity for Corvus to showcase its strategic direction, innovative therapies, and long-term vision to a broader audience. During this time, members of the leadership team will discuss the company’s goals and the promising developments in its research areas.
Webcast Availability
A live webcast of the fireside chat will be accessible to the public and will remain available for 90 days following the event. This approach enhances transparency and allows interested parties to gain insights into the company’s future endeavors. Investors can access the webcast through the investor relations section of the Corvus Pharmaceuticals website.
Corvus Pharmaceuticals: Pioneering New Therapies
Founded with a mission to develop innovative treatments, Corvus Pharmaceuticals is at the forefront of exploring ITK inhibition as a novel approach to immunotherapy. The company's flagship product, soquelitinib, represents a significant advancement in treatment options for various cancers and immune diseases. What sets this candidate apart is its targeted mechanism of action that selectively inhibits ITK, potentially increasing efficacy while minimizing adverse effects.
Focus on Cancer Therapy Development
Besides soquelitinib, Corvus is actively advancing its pipeline with other clinical-stage candidates developed for various cancer indications. Each candidate is designed to tackle specific challenges associated with cancer therapies, indicating Corvus's commitment to addressing unmet medical needs.
Investor Relations and Communication
Investor engagement is a priority for Corvus Pharmaceuticals, as evidenced by their proactive approach to communication and outreach. Leiv Lea, the Chief Financial Officer, emphasizes the importance of building strong relationships with investors. He encourages interested parties to reach out to learn more about Corvus’s innovative projects and business strategies.
Investor Contact Information
For inquiries related to investment, individuals are encouraged to contact Leiv Lea at Corvus Pharmaceuticals. He can be reached at +1-650-900-4522 or via email at llea@corvuspharma.com.
Media Relations
Additionally, for media-related inquiries, Sheryl Seapy from Real Chemistry is available at +1-949-903-4750. The media contact is crucial for maintaining the flow of information regarding Corvus’s developments and future plans.
Frequently Asked Questions
What is the focus of the upcoming conference for Corvus Pharmaceuticals?
Corvus Pharmaceuticals will engage in one-on-one meetings and participate in a fireside chat to discuss their innovative therapies and business strategies.
When will the fireside chat take place?
The fireside chat is scheduled for November 10, 2025, at 8:30 am ET.
How can I access the webcast of the fireside chat?
The webcast will be available live and for 90 days afterward on the Corvus Pharmaceuticals investor relations website.
What is soquelitinib?
Soquelitinib is Corvus Pharmaceuticals' lead candidate, aimed at inhibiting ITK for the treatment of various cancers and immune diseases.
Who can I contact for investor-related inquiries?
Please contact Leiv Lea, Chief Financial Officer at Corvus Pharmaceuticals, for any investor-related questions.
